You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Colorcon
Johnson and Johnson
Boehringer Ingelheim

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Pfizer Company Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-008 Jan 30, 2004 AB RX Yes Yes   Start Trial   Start Trial
Pfizer CEFOBID cefoperazone sodium INJECTABLE;INJECTION 050551-001 Nov 18, 1982 DISCN No No   Start Trial   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-002 Nov 21, 2018 RX Yes Yes 8,148,401   Start Trial Y Y   Start Trial
Pfizer PFIZERPEN-AS penicillin g procaine INJECTABLE;INJECTION 060286-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 AB RX Yes No   Start Trial   Start Trial
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-008 Jan 30, 2004 5,273,995*PED   Start Trial
Pfizer TROVAN trovafloxacin mesylate TABLET;ORAL 020759-001 Dec 18, 1997 6,187,341   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 6,011,049   Start Trial
Pfizer ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-001 Dec 30, 1991 4,536,518*PED   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 4,024,175   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 4,572,912   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 2005-11-09
➤ Subscribe Tablets 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg ➤ Subscribe 2006-12-29
➤ Subscribe Tablets 2.5 mg/40 mg ➤ Subscribe 2009-09-17
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2004-11-19
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 2010-03-29
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2009-04-07
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Tablets 100 mg ➤ Subscribe 2004-10-25
Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746999 CR 2019 00043 Denmark   Start Trial PRODUCT NAME: DACOMITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1354 20190404
1507558 12C0033 France   Start Trial PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
0792290 0491022-0 Sweden   Start Trial PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
2822953 301006 Netherlands   Start Trial PRODUCT NAME: LORLATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1355 20190508
0473687 3/1999 Austria   Start Trial PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
0473687 SPC/GB98/030 United Kingdom   Start Trial PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Express Scripts
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.